Efficacy and Safety of 4 Weeks Treatment With Inhaled BI 1744 CL in Patients With COPD.

NCT00452400 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

409

Enrollment

INDUSTRY

Sponsor class

Conditions

Pulmonary Disease, Chronic Obstructive
Asthma

Interventions

DRUG: BI 1744CL

Sponsor

Boehringer Ingelheim